Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Fludarabine | Fludara | FAMP|Fludarabine phosphate | Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) | |
NGFR-transduced autologous T lymphocytes | NGFR-transduced autologous T lymphocytes are autologous T-lymphocytes engineered to express nerve growth factor receptor, which may result in an antitumor immune response and killing of tumor cells expressing nerve growth factor (NCI Drug Dictionary). | |||
TGFbDNRII-transduced autologous TILs | TGFbDNRII-transduced autologous TILs are patient-derived tumor infiltrating lymphocytes engineered to express a dominant negative version of transforming growth factor beta receptor (TGFbDNRII), which potentially results in enhanced anti-tumor immune activity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01955460 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |